503B Compounder Set to Manufacture Products Embedded with RFID tags Compatible with KitCheck Scanning Technology

ARLINGTON, Va., Dec. 8, 2021 /PRNewswire/ — Bluesight, the market leader in software solutions for item-level visibility in the pharmaceutical space, in collaboration with Fagron Sterile Services US (FSS), a leading 503B manufacturer, is pleased to announce that Radio Frequency Identification (RFID)-tagged products will be available in United States hospitals in February 2022.

Medications labeled with RFID tags at the manufacturer level ensures that there is item-level visibility of drug products throughout their dynamic lifecycle. This means better patient safety, optimized inventory for hospitals, cost savings, and dramatically increased workflow simplicity and efficiency.

RFID tags, in combination with the KitCheck technology, store information for each dose, including expiration date, lot number, NDC, and refrigeration date, so restocking, inventory management, and managing shortages and recalls is as seamless as possible. COVID-19 has continued to shine a light on the importance of item-level inventory management in the hospital, with KitCheck customers well poised to deal with the difficulty inventory challenges the pandemic has caused.

“We are so excited to be able to offer RFID-tagged medications for our hospital customers, and even more excited to be working with Fagron to expand the offering of pre-tagged 503B products,” said Kevin MacDonald, CEO and Co-Founder of Bluesight.